Steven had a newborn grandchild and two arms that shook too much to hold him.
Steven had a newborn grandchild and two arms that shook too much to hold him. He also had CIDP, a progressive neurological disease, and no access to the $20,000-per-month medication keeping him functional. What followed was an unexpected outcome. It came from a personalized CIDP supplement protocol. It was built on his own genetics and lab data, reviewed by licensed clinicians.
The tremors hit hardest at night. To stop shaking long enough to sleep, Steven relied on heavy muscle relaxers. He used a motorized wheelchair because his coordination and upper body strength were too far gone for a manual one. He could not dress himself, and getting out of bed required help from his wife.
“Take away a person’s ability to care for themselves and you take away a lot of their seeming value,” Steven says. “I couldn’t hold my grandbaby. I was afraid of dropping him because I didn’t have the control over my arms.”
Twenty years without an answer
Steven’s neurological decline began roughly twenty years ago with weakness in his lower extremities and worsening balance. Doctors initially treated it as Guillain-Barré Syndrome. He responded to steroids and left the hospital. But when symptoms returned years later, that diagnosis fell apart. Guillain-Barré does not typically recur.
A decade of inconclusive testing followed. CBC differentials, metabolic panels, nerve conduction studies, and full-body MRIs all came back normal. The only early signal was elevated cerebrospinal fluid protein from a spinal tap. Then, finally, imaging revealed lesions in the brain and gray matter artifacts on MRI. A neurologist diagnosed him with Chronic Inflammatory Demyelinating Polyneuropathy, or CIDP. It is a chronic autoimmune condition. The immune system attacks the myelin sheath surrounding peripheral nerves, causing progressive weakness, numbness, and loss of motor function. A CIDP supplement protocol is sometimes discussed for management.
By that point, Steven had already spent a decade in treatment without a confirmed diagnosis.
Three medications and a $20,000 bill
Over the years, Steven tried three immunomodulatory therapies. Privigen triggered aseptic meningitis, so his team discontinued it. Vyvgart Hytrulo produced no benefit at all. He kept declining.
Hizentra finally stopped the progression. Delivered subcutaneously at 32 grams per week, it offered modest mobility improvement. However, each infusion wiped him out for about two days, so he scheduled treatments on Fridays to recover over the weekend. Even so, reflex tests still showed no response. His doctors told him he would likely need the treatment long-term.
The cost: approximately $20,000 per month.
When Steven lost his insurance coverage, that figure became an immediate crisis. A trusted contact directed him to the manufacturer for compassionate access, but the manufacturer required Medicaid approval first. So Steven applied for Medicaid. Four months later, no approval had arrived, and the manufacturer would not release the medication without it.
“The first thought was: I’m screwed,” he says. “How am I going to live? How am I ever going to provide for my family?”
He had a confirmed progressive disease, a treatment that managed it but did not reverse it, and no way to pay for either.
A data-driven CIDP supplement protocol
A trusted personal contact introduced Steven to Nexus Health. He was skeptical. Over two decades, he had tried alternative medicine approaches multiple times, and the results ranged from negligible to negative.
Still, he started the process. Nexus Health began with a comprehensive fasting blood panel and his existing ancestry-based DNA data. The platform’s clinical reasoning engine then analyzed those biomarkers alongside his genetic data to build a personalized CIDP supplement protocol. Licensed clinicians reviewed it before it reached him.
The protocol follows three phases: Stabilize, Repair, and Optimize. Phase 1 addresses foundational stabilization, including gut health, methylation priming, circadian rhythm support, and nutrient loading. Phase 2 targets core dysfunctions the analysis identified. Phase 3 focuses on long-term optimization.
What struck Steven most was the structure. For years, conventional neurology had felt like “spray and pray.” This was different. Each intervention had a clear rationale, a defined sequence, and a clinician sign-off before it reached him.
His monthly cost for the CIDP supplement protocol: approximately $100 to $200.
What the labs showed
The team conducted three blood draws across the protocol period to track progress objectively.
Within the first seven weeks, Steven’s inflammatory markers moved measurably. His high-sensitivity C-reactive protein dropped by nearly 50 percent. His erythrocyte sedimentation rate declined. TNF-alpha, a cytokine tied to neuroinflammation, shifted from elevated to within functional range. Homocysteine improved, which indicated better methylation efficiency. TSH also moved toward better thyroid signaling.
A December follow-up confirmed the protocol had not introduced metabolic stress. Liver function, kidney filtration, and fasting glucose all stayed stable within normal ranges.
Notably, Steven achieved all of this without any concurrent pharmaceutical intervention. No immunoglobulin therapy, no steroids, no prescription medication of any kind.
What the labs showed after 7 weeks
↓ 50%
hs-CRP inflammatory marker
↓
ESR and TNF-alpha normalized
$100/mo
vs $20,000/mo pharmaceutical
The finding his neurologist did not expect
About seven months into the CIDP supplement protocol, Steven returned to his neurologist for a routine evaluation. During the exam, the neurologist tested his reflexes. In every prior visit, those tests had shown nothing.
This time, a response came back.
“For the first time in years, when he hammered on me, I was reflexive,” Steven says. “CIDP is a progressive disease. It doesn’t go backwards. Seeing that response after all this time was pretty show-stopping.”
His neurologist had previously expressed skepticism about supplement-based interventions. After this visit, he advised Steven to continue the current protocol.
Where he is now
Today, Steven no longer uses a wheelchair. He handles daily activities on his own, including dressing and getting out of bed. He has played soccer. He has held his grandson.
He still lives with CIDP. This is not a story of cure. However, the frequency and severity of his symptomatic episodes have dropped, flare recovery is faster, and his functional baseline looks nothing like it did a year ago.
“You’re not alone. It’s not hopeless,” Steven says. “There are ways to treat chronic illness that are truly data-backed and science-backed and medically validated by a clinician.”
Download the Full Case Study
This article presents a single-patient observational case study. Results are specific to this individual and his unique biological profile, medical history, and protocol adherence. They should not be generalized to other patients without independent clinical evaluation. Steven is a co-founder of Nexus Health. His role and personal stake in the company are disclosed in the interest of full transparency.